Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Age-specific progression of nigrostriatal dysfunction in Parkinson's disease.

de la Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, Mak E, McKenzie J, McCormick S, Sossi V, Ruth TJ, Lee CS, Calne DB, Stoessl AJ.

Ann Neurol. 2011 May;69(5):803-10. doi: 10.1002/ana.22284. Epub 2011 Jan 18.

PMID:
21246604
2.

Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.

Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, McCormick S, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Stoessl AJ.

Brain. 2011 Nov;134(Pt 11):3290-8. doi: 10.1093/brain/awr233.

PMID:
22075521
3.

Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Bohnen NI, Müller ML, Zarzhevsky N, Koeppe RA, Bogan CW, Kilbourn MR, Frey KA, Albin RL.

Brain. 2011 Aug;134(Pt 8):2358-65. doi: 10.1093/brain/awr139. Epub 2011 Jun 8.

4.

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ.

Ann Neurol. 2000 Apr;47(4):493-503.

PMID:
10762161
5.

Age and severity of nigrostriatal damage at onset of Parkinson's disease.

De La Fuente-Fernández R, Lim AS, Sossi V, Adam MJ, Ruth TJ, Calne DB, Stoessl AJ, Lee CS.

Synapse. 2003 Feb;47(2):152-8.

PMID:
12454953
6.

Dopaminergic function and progression of Parkinson's disease: PET findings.

Biju G, de la Fuente-Fernández R.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S38-40. doi: 10.1016/S1353-8020(09)70833-8. Review.

PMID:
20123555
7.

Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease.

Martin WR, Wieler M, Stoessl AJ, Schulzer M.

Ann Neurol. 2008 Mar;63(3):388-94. doi: 10.1002/ana.21320.

PMID:
18240153
8.

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ.

Brain. 2005 Dec;128(Pt 12):2777-85. Epub 2005 Aug 4.

PMID:
16081470
9.

Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome.

Albin RL, Koeppe RA, Wernette K, Zhuang W, Nichols T, Kilbourn MR, Frey KA.

Neurology. 2009 Apr 21;72(16):1390-6. doi: 10.1212/WNL.0b013e3181a187dd.

10.

Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.

Scherfler C, Esterhammer R, Nocker M, Mahlknecht P, Stockner H, Warwitz B, Spielberger S, Pinter B, Donnemiller E, Decristoforo C, Virgolini I, Schocke M, Poewe W, Seppi K.

Brain. 2013 Oct;136(Pt 10):3028-37. doi: 10.1093/brain/awt234. Epub 2013 Sep 6.

PMID:
24014521
11.

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.

Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE.

Ann Neurol. 1996 Dec;40(6):873-84.

12.

Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.

Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA.

J Cereb Blood Flow Metab. 2006 Sep;26(9):1198-212. Epub 2006 Jan 18.

PMID:
16421508
13.

Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.

Lee CS, Schulzer M, de la Fuente-Fernández R, Mak E, Kuramoto L, Sossi V, Ruth TJ, Calne DB, Stoessl AJ.

Arch Neurol. 2004 Dec;61(12):1920-5.

PMID:
15596613
14.

VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.

De La Fuente-Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, Ruth TJ, Stoessl AJ.

Synapse. 2003 Jul;49(1):20-8.

PMID:
12710012
15.

In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.

Lin SC, Lin KJ, Hsiao IT, Hsieh CJ, Lin WY, Lu CS, Wey SP, Yen TC, Kung MP, Weng YH.

J Nucl Med. 2014 Jan;55(1):73-9. doi: 10.2967/jnumed.113.121897. Epub 2013 Nov 28.

16.

Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease.

Hu MT, Scherfler C, Khan NL, Hajnal JV, Lees AJ, Quinn N, Wood NW, Brooks DJ.

Mov Disord. 2006 Mar;21(3):299-305.

PMID:
16211589
17.

Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.

Caminiti SP, Presotto L, Baroncini D, Garibotto V, Moresco RM, Gianolli L, Volonté MA, Antonini A, Perani D.

Neuroimage Clin. 2017 Mar 27;14:734-740. doi: 10.1016/j.nicl.2017.03.011. eCollection 2017.

18.

Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study.

Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, Bhatia KP, Quinn NP, Lees AJ, Piccini P.

Mov Disord. 2009 Nov 15;24(15):2260-6. doi: 10.1002/mds.22817.

PMID:
19845000
19.

Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease.

Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY.

J Neurol. 2007 Jan;254(1):84-90. Epub 2007 Feb 14.

PMID:
17508142
20.

History of falls in Parkinson disease is associated with reduced cholinergic activity.

Bohnen NI, Müller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL.

Neurology. 2009 Nov 17;73(20):1670-6. doi: 10.1212/WNL.0b013e3181c1ded6.

Supplemental Content

Support Center